These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21211076)

  • 41. The costs of care in haematological cancers: Health economic issues.
    Fey MF
    Hematol Oncol; 2017 Jun; 35 Suppl 1():15-19. PubMed ID: 28591414
    [No Abstract]   [Full Text] [Related]  

  • 42. Far, far away land: palliative care as a human right.
    Larkin P
    Int J Palliat Nurs; 2013 Jun; 19(6):263. PubMed ID: 24151735
    [No Abstract]   [Full Text] [Related]  

  • 43. HIV and lymphoma: from oncological futility to treatment.
    Noy A
    Lancet HIV; 2020 Sep; 7(9):e598-e600. PubMed ID: 32791047
    [No Abstract]   [Full Text] [Related]  

  • 44. Improving haematological care for adolescents.
    The Lancet Haematology
    Lancet Haematol; 2023 Dec; 10(12):e941. PubMed ID: 38030312
    [No Abstract]   [Full Text] [Related]  

  • 45. A human rights-based approach.
    McIlfatrick S
    Int J Palliat Nurs; 2023 Dec; 29(12):569. PubMed ID: 38085614
    [No Abstract]   [Full Text] [Related]  

  • 46. [The GELF is over, long live the GETIF!!].
    Guibert N; Dutau H; Vergnon JM
    Rev Mal Respir; 2021 Feb; 38(2):131-133. PubMed ID: 33581984
    [No Abstract]   [Full Text] [Related]  

  • 47. Economic and cost-effectiveness issues in breast cancer treatment.
    Hillner BE
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost effectiveness, chemotherapy, and the clinician.
    Griggs JJ; Sorbero ME
    Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
    [No Abstract]   [Full Text] [Related]  

  • 50. [Cost of cancer in France: pharmaceutical expenditure as part of global patients' care].
    Zambrowski JJ
    Bull Cancer; 2008 May; 95(5):535-41. PubMed ID: 18541518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Costs of chemotherapy in the treatment of colorectal cancer.
    Jansman FG; Postma MJ
    Eur J Health Econ; 2006 Jun; 7(2):145-6. PubMed ID: 16699776
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treat haematology patients as long as possible].
    Huijgens PC
    Ned Tijdschr Geneeskd; 2010; 154(51-52):A2882. PubMed ID: 21211076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intensive care for patients with medical complications of haematological malignancy: is it worth it?
    Hinds CJ; Martin R; Quinton P
    Schweiz Med Wochenschr; 1998 Sep; 128(39):1467-73. PubMed ID: 9793166
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.